331 related articles for article (PubMed ID: 33335528)
1. Antigen Specificity Enhances Disease Control by Tregs in Vitiligo.
Mukhatayev Z; Dellacecca ER; Cosgrove C; Shivde R; Jaishankar D; Pontarolo-Maag K; Eby JM; Henning SW; Ostapchuk YO; Cedercreutz K; Issanov A; Mehrotra S; Overbeck A; Junghans RP; Leventhal JR; Le Poole IC
Front Immunol; 2020; 11():581433. PubMed ID: 33335528
[TBL] [Abstract][Full Text] [Related]
2. A quantitative increase in regulatory T cells controls development of vitiligo.
Chatterjee S; Eby JM; Al-Khami AA; Soloshchenko M; Kang HK; Kaur N; Naga OS; Murali A; Nishimura MI; Caroline Le Poole I; Mehrotra S
J Invest Dermatol; 2014 May; 134(5):1285-1294. PubMed ID: 24366614
[TBL] [Abstract][Full Text] [Related]
3. Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo.
Lili Y; Yi W; Ji Y; Yue S; Weimin S; Ming L
PLoS One; 2012; 7(5):e37513. PubMed ID: 22649532
[TBL] [Abstract][Full Text] [Related]
4. HO-1 regulates the function of Treg: Association with the immune intolerance in vitiligo.
Zhang Q; Cui T; Chang Y; Zhang W; Li S; He Y; Li B; Liu L; Wang G; Gao T; Li C; Jian Z
J Cell Mol Med; 2018 Sep; 22(9):4335-4343. PubMed ID: 29974998
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients.
van den Boorn JG; Konijnenberg D; Dellemijn TA; van der Veen JP; Bos JD; Melief CJ; Vyth-Dreese FA; Luiten RM
J Invest Dermatol; 2009 Sep; 129(9):2220-32. PubMed ID: 19242513
[TBL] [Abstract][Full Text] [Related]
6. Replenishing Regulatory T Cells to Halt Depigmentation in Vitiligo.
Le Poole IC; Mehrotra S
J Investig Dermatol Symp Proc; 2017 Oct; 18(2):S38-S45. PubMed ID: 28941492
[TBL] [Abstract][Full Text] [Related]
7. CCL22 to Activate Treg Migration and Suppress Depigmentation in Vitiligo.
Eby JM; Kang HK; Tully ST; Bindeman WE; Peiffer DS; Chatterjee S; Mehrotra S; Le Poole IC
J Invest Dermatol; 2015 Jun; 135(6):1574-1580. PubMed ID: 25634358
[TBL] [Abstract][Full Text] [Related]
8. Mutant HSP70 reverses autoimmune depigmentation in vitiligo.
Mosenson JA; Zloza A; Nieland JD; Garrett-Mayer E; Eby JM; Huelsmann EJ; Kumar P; Denman CJ; Lacek AT; Kohlhapp FJ; Alamiri A; Hughes T; Bines SD; Kaufman HL; Overbeck A; Mehrotra S; Hernandez C; Nishimura MI; Guevara-Patino JA; Le Poole IC
Sci Transl Med; 2013 Feb; 5(174):174ra28. PubMed ID: 23447019
[TBL] [Abstract][Full Text] [Related]
9. Regulatory T cells from active non-segmental vitiligo exhibit lower suppressive ability on CD8+CLA+ T cells.
Lin M; Zhang BX; Shen N; Dong XJ; Zhang C; Qi XY; Zhu J; Li YZ; Man MQ; Tu CX
Eur J Dermatol; 2014; 24(6):676-82. PubMed ID: 25335433
[TBL] [Abstract][Full Text] [Related]
10. Expansion of vitiligo lesions is associated with reduced epidermal CDw60 expression and increased expression of HLA-DR in perilesional skin.
Le Poole IC; Stennett LS; Bonish BK; Dee L; Robinson JK; Hernandez C; Hann SK; Nickoloff BJ
Br J Dermatol; 2003 Oct; 149(4):739-48. PubMed ID: 14616364
[TBL] [Abstract][Full Text] [Related]
11. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo.
Ogg GS; Rod Dunbar P; Romero P; Chen JL; Cerundolo V
J Exp Med; 1998 Sep; 188(6):1203-8. PubMed ID: 9743539
[TBL] [Abstract][Full Text] [Related]
12. Regulatory T Cells Require CCR6 for Skin Migration and Local Suppression of Vitiligo.
Essien KI; Katz EL; Strassner JP; Harris JE
J Invest Dermatol; 2022 Dec; 142(12):3158-3166.e7. PubMed ID: 35777498
[TBL] [Abstract][Full Text] [Related]
13. Regulatory T cells in vitiligo: Implications for pathogenesis and therapeutics.
Dwivedi M; Kemp EH; Laddha NC; Mansuri MS; Weetman AP; Begum R
Autoimmun Rev; 2015 Jan; 14(1):49-56. PubMed ID: 25308528
[TBL] [Abstract][Full Text] [Related]
14. Regulating the regulators: Is introduction of an antigen-specific approach in regulatory T cells the next step to treat autoimmunity?
Janssens I; Cools N
Cell Immunol; 2020 Dec; 358():104236. PubMed ID: 33137651
[TBL] [Abstract][Full Text] [Related]
15. Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma.
Byrne KT; Zhang P; Steinberg SM; Turk MJ
J Immunol; 2014 Feb; 192(4):1433-9. PubMed ID: 24403535
[TBL] [Abstract][Full Text] [Related]
16. Compromised melanocyte survival due to decreased suppression of CD4
Shah F; Giri PS; Bharti AH; Dwivedi M
Exp Dermatol; 2024 Jan; 33(1):e14982. PubMed ID: 37994568
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance.
Zhang Q; Lu W; Liang CL; Chen Y; Liu H; Qiu F; Dai Z
Front Immunol; 2018; 9():2359. PubMed ID: 30369931
[TBL] [Abstract][Full Text] [Related]
18. Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation.
Eby JM; Kang HK; Klarquist J; Chatterjee S; Mosenson JA; Nishimura MI; Garrett-Mayer E; Longley BJ; Engelhard VH; Mehrotra S; Le Poole IC
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1075-85. PubMed ID: 24935676
[TBL] [Abstract][Full Text] [Related]
19. Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo.
Wańkowicz-Kalińska A; van den Wijngaard RM; Tigges BJ; Westerhof W; Ogg GS; Cerundolo V; Storkus WJ; Das PK
Lab Invest; 2003 May; 83(5):683-95. PubMed ID: 12746478
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor costimulation domains modulate human regulatory T cell function.
Boroughs AC; Larson RC; Choi BD; Bouffard AA; Riley LS; Schiferle E; Kulkarni AS; Cetrulo CL; Ting D; Blazar BR; Demehri S; Maus MV
JCI Insight; 2019 Mar; 5(8):. PubMed ID: 30869654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
